Trials / Recruiting
RecruitingNCT06640257
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of SHR-1314 Injection in Adults With Active Psoriatic Arthritis
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1314 injection | SHR-1314 injection |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2024-11-04
- Primary completion
- 2026-04-30
- Completion
- 2026-06-30
- First posted
- 2024-10-15
- Last updated
- 2024-11-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06640257. Inclusion in this directory is not an endorsement.